Eli Lilly pays $690M to settle Zyprexa claims
Brown & Cruppen Press Release - June 9, 2005
Eli Lilly announced that it will settle about three-quarters of the liability claims stemming from claims that the label on Zyprexa medication boxes failed to provide adequate warning that the drug could put patients more at risk for developing diabetes.  Brown & Crouppen is assisting Zyprexa victims with claims.

Drugs And Your Heart
eDiets.com - Apr 22, 2005
"Psychotropic drugs may be bad for your heart. According to the American Diabetes Association -- the American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity issued a consensus statement cautioning doctors that newer antipsychotic drugs increase the risk for diabetes and related metabolic disorders. The drugs were clozapine (Clozaril) and olanzapine (Zyprexa). The panel came to the conclusion after presentations from 14 experts as well as representatives from pharmaceutical companies and the Food and Drug Administration."

Lilly: Zyprexa And Beyond
Forbes - Apr 14, 2005
"Lilly's shares are more than 25% off their 52-week high, mostly because of concerns about the company's lead drug, the antipsychotic Zyprexa. ...  Zyprexa, which is used for the treatment of serious psychiatric disorders, such as schizophrenia and bipolar disorder, accounted for 32% of Lilly's revenue last year."

Zyprexa IM Caution Issued in Some Countries But Not US
Psychiatric News, CA - Apr 14, 2005
"At least 49 adverse events, some of which were related to cardiac and respiratory depression and some of which have been fatal, have been associated with inappropriate use of the intramuscular formulation of olanzapine, marketed as Zyprexa... If you are a psychiatrist in Canada, the United Kingdom, or Europe, that may be old news: you might have read about these problems in "Dear Healthcare Professional" letters requested by regulatory authorities in Canada and Europe, distributed widely to prescribing psychiatrists, and signed by Zyprexa manufacture Elli Lilly and Co."

FDA issues warning on Lilly anti-psychotic drug
WTHR, IN - Apr 12, 2005
... of atypical anti-psychotic drugs to change their labeling for Zyprexa and other drugs. The agency wants them to add a boxed warning noting the risks and that ...

FDA Calls for Warning on Antipsychotic Drugs
Reuters - Apr 11, 2005
The black box warning affects Eli Lilly and Co.'s Zyprexa and Symbyax ... "The FDA is moving toward increasing awareness of various side effects by updating labels ...

FDA warns elderly of anti-psychotic drug risks
Indianapolis Star - Apr 12, 2005
... for Indianapolis-based Eli Lilly and Co., the maker of Zyprexa, said the ... the company also changed the drug's label last year to reiterate those higher risks. ...

Popular Drugs for Dementia Tied to Deaths
New York Times
... Zyprexa is the biggest drug expense for many state Medicaid programs, the ... likely to cause tardive dyskinesia, and worries about other side effects are mounting ...

Psychiatric Drugs: The New Pharmacopoeia
Newsweek - Apr 16, 2005
... The most common side effects, such as appetite suppression, are easily managed ... Antipsychotics like olanzapine (Zyprexa) and risperidone (Risperdal) can cause ...

FDA: Medication Errors Alert (January 26, 2005)
"Eli Lilly and Company has received reports of medication dispensing or prescribing errors between our atypical antipsychotic ZyPREXA (olanzapine) and the antihistamine ZYRTEC (cetirizine HCI) marketed by Pfizer. These reports include instances where Zyprexa was incorrectly dispensed for Zyrtec and vice versa, leading to various adverse events in some instances. These errors could result in unnecessary adverse events or potential relapse in patients suffering from schizophrenia or bipolar disorder."


Brown & Crouppen: Prescription Drug Injury Lawyers
Brown & Crouppen has been building a reputation for success with personal injury clients for over 25 years. Today, we are one of mid-America’s largest personal injury law firms with over 70 legal professionals and five offices throughout Missouri and Illinois. A large area of our concentration is dangerous drug litigation involving manufacturers and suppliers of unsafe drugs and products.  If you have been injured by a dangerous drug, the manufacturer may have failed in its duty to design, make, inspect and label the product appropriately.

You can count on the lawyers of Brown & Crouppen for top-notch legal skills and our commitment to making the justice system work for our clients. If you have legal concerns and would like to benefit from the support of a strong team of legal professionals, please contact us online or call our office today at 1-800-536-HELP.